NIH R01 · 2025
Mechanistic and therapeutic role of the CD137-CD137L axis in Type 1 Diabetes
PROJECT SUMMARY Our labs have been extensively studying CD137-CD137L immune signaling in T1D. These studies have uncovered additional critical mechanistic issues which we propose to study in this application. The regulation of the CD137-CD137L system is complex, mainly because both CD137 and CD137L signal into the cells expressing them, which must be taken into account in any analysis of CD137 and CD137L signaling. In our preliminary data we identify many specific instances in which the effect of CD137 or CD137L signaling differs according to the type of immune cells. FOXP3+ regulatory CD4 T cells (Tregs), antigen-presenting cells (APCs), and effector T cells all express different levels of…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.